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rognostic Factors in
atients With Implantable
ardioverter-Defibrillators
e have read with great interest the report by Borleffs et al. (1)
bout atrial fibrillation (AF) and mortality in patients with
mplantable cardioverter-defibrillators (ICDs). The investigators
ound that AF is a prognostic factor in ICD patients, but some
ssues need to be considered.
The association between higher New York Heart Association
NYHA) functional class and poor outcome in heart failure is well
nown. Among unselected patients with NYHA functional class
I, III, and IV heart failure, mortality was 7.1%, 15.0%, and 28.0%,
espectively (2). In the study of Borleffs et al. (1), although the
roportion of patients in NYHA functional classes III and IV in
he permanent AF group was 56%, this proportion was 35% in the
aroxysmal AF group and 33% in the non-AF group. The
nvestigators state that the mortality rates in these groups were
5%, 13%, and 10%, respectively. However, it is possible that
ndependent of other prognostic factors, the discrepancy in the
roportions of patients in NYHA functional classes III and IV in
F groups may be a contributing factor to the differing mortality
ates. Therefore, specific mortality rates in NYHA groups are
eeded to correctly interpret the study’s results.
Another important issue is the types of devices used. Although
orleffs et al. (1) state the rates of single- and dual-chamber ICDs,
ome points are unclear. The investigators concluded that patients
ith permanent AF showed more than twice the risk for appro-
riate and inappropriate therapies compared with patients with no Histories of AF. However, all ICD patients, without mention of
he manufacturers and models of ICDs, were included in the study.
t is known that dual-chamber ICDs (DDD[R] ICDs and cardiac
esynchronization therapy ICDs) can easily discriminate supraven-
ricular tachycardia from ventricular tachycardia. However, single-
hamber ICDs can discriminate supraventricular tachycardia from
entricular tachycardia by using different software algorithms. For
xample, Medtronic (Minneapolis, Minnesota) ICDs use mor-
hology, stability, onset, and wavelet algorithms; Boston Scientific
Natick, Massachusetts) ICDs use atrial view, stability, and onset
lgorithms; St. Jude Medical (St. Paul, Minnesota) ICDs use
tability, onset, and atrioventricular rate branch algorithms; and
iotronik (Berlin, Germany) ICDs use stability, onset, and sus-
ained ventricular tachycardia timer algorithms (3–6). Therefore,
upraventricular tachycardia discrimination performance is also
ifferent among manufacturers and models. In addition, some
ual-chamber ICDs (e.g., Medtronic’s Virtuso, Secura, and En-
rust models and St. Jude’s Current DR and Atlas II models) can
onvert atrial tachyarrhythmias to sinus rhythm using atrial anti-
achycardia pacing and atrial cardioversion. The use of different
anufacturers and device types would result in different AF
pisodes and appropriate and inappropriate therapies. All of these
ifferences might affect the results of the study by Borleffs et al. (1).
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e thank Dr. Kalay and colleagues for their interest in and
ositive comments on our study (1). We fully agree that New York
eart Association (NYHA) functional class should be considered
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August 17, 2010:680–2confounder, because NYHA functional class was correlated with
he occurrence of atrial fibrillation, as well as with mortality and
he incidence of ventricular arrhythmia (2,3). Therefore, in the
ssessment of the correlations between different types of atrial
brillation and these end points, we corrected for NYHA func-
ional class. Additional potential confounders, such as age, sex,
enal clearance, left ventricular ejection fraction, QRS duration,
nd the use of beta-blockers, were corrected for as well.
Furthermore, Dr. Kalay and colleagues state that dual-chamber
mplantable cardioverter-defibrillators (ICDs) can easily discrimi-
ate supraventricular tachycardia from ventricular tachycardia.
owever, published research is less decisive. Theuns et al. (4)
erformed a prospective, randomized study to evaluate the perfor-
ance of tachyarrhythmia detection algorithms in single-chamber
nd dual-chamber ICDs but did not find a significant reduction in
he number of inappropriate classifications or inappropriately
elivered therapy. Others have reported similar results (5,6). In
ontrast, a randomized trial conducted by Friedman et al. (7)
emonstrated a small reduction in inappropriate supraventricular
achyarrhythmia detection (8.6%) in comparison with single-chamber
CDs. In our opinion, it is too premature to conclude that dual-
hamber ICDs are superior to single-chamber ICDs regarding dis-
rimination between supraventricular and ventricular arrhythmias.
Although one can argue that devices from different manufac-
urers use different algorithms, which in theory may influence their
erformance regarding the discrimination between atrial and
entricular tachycardias, no data are available supporting this
heory. Nonetheless, at our center, we strive for consistent device
rogramming, unless clinically indicated (i.e., hemodynamically
ell-tolerated ventricular tachycardia at a high rate; ventricular
achycardia in the monitor zone) (8). Moreover, additional dis-
riminators are standard activated in all dual-chamber ICDs.
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